Table 4.
Univariable overall survival*
| Characteristic | N | Events | HR (95% CI) |
|---|---|---|---|
| Age at surgery, y | 51 | 17 | 1.0 (0.98–1.06) |
| BMI, kg/m2 | 45 | 12 | 1.0 (0.94–1.09) |
| Grade | |||
| 1 (Ref) | 12 | 2 | Ref |
| 2 | 15 | 5 | 2.5 (0.5–13.1) |
| 3 | 13 | 6 | 3.8 (0.8–19.0) |
| Associated borderline tumor | |||
| Absent (Ref) | 21 | 7 | Ref |
| Present | 27 | 8 | 1.0 (0.4–2.8) |
| Tumor debulking status | |||
| No gross residual (Ref) | 43 | 11 | Ref |
| Optimal (< 1 cm residual) | 2 | 1 | 16.4 (1.6–164.4) |
| Suboptimal | 4 | 4 | 5.5 (1.8–17.5) |
| FIGO stage | |||
| I (Ref) | 30 | 5 | Ref |
| II | 9 | 4 | 2.8 (0.7–10.4) |
| III or IV | 11 | 7 | 5.4 (1.7–17.2) |
| Chemotherapy regimen type | |||
| Gynecologic (Ref) | 26 | 14 | Ref |
| Gastrointestinal | 25 | 3 | 0.2 (0.1–0.8) |
| Bevacizumab | |||
| No (Ref) | 37 | 14 | Ref |
| Yes | 14 | 3 | 0.6 (0.2–2.0) |
Y, years; BMI, body mass index; Ref, reference; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; CI, confidence interval.
*
51 patients had data available for overall survival.